Immunization cost efficiency in influenza economics

Apply

Immunization cost efficiency in influenza economics

Journal Title: JOURNAL OF CONTEMPORARY MEDICINE - Year 2018, Vol 8, Issue 2

Abstract

Influenza is an acute upper and lower respiratory tract infectious disease caused by influenza A, B, C and D viruses, seasonal outbreaks and pandemics. Influenza virus usually causes sporadic infections in humans. If viruses infecting animals adapt to humans and become infectious, they may cause pandemics. Following a short incubation period, the disease may lead to an asymptomatic form and, in its severest form, to death, depending on the characteristics of both the virus and the host. Typical influenza outbreaks become apparent within 2-3 weeks and terminate in 5-6 weeks. As the pandemic progresses, it results in higher rates of hospitalization and deaths due to complications in the respiratory and circulatory systems. Thousands of patients are admitted to hospitals in the United States and European countries annually for treatment of seasonal influenza. This creates a far greater effect in developing countries. About 20% of the world’s population is annually infected with influenza viruses. A large majority of them are admitted to hospitals and undergo an outpatient or inpatient treatment. Both treatment and vaccination impose an economic burden on countries, society and the health system. Which is a greater economic burden; diagnosis and treatment of influenza or seasonal influenza vaccination? Studies are conducted all over the world to determine which one is more cost effective. Determination of which approach to use for reducing influenza-related economic burden will guide the policies and strategies of countries. This study will assess seasonal influenza infections as well as economic impacts of influenza infections and vaccination.

Authors and Affiliations

Selma Altındiş, Gülay Şimşek

Keywords

EP ID EP423444
DOI 10.16899/gopctd.379753
Views 96
Downloads 0